Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06975722 · ClinicalTrials.gov registry record · Phase 2
A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis
A Phase 2 study of Ulcerative Colitis, sponsored by Sanofi.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 99
- Enrollment target
- 20
- Study locations
NCT06975722: Recruiting Phase 2 study of Ulcerative Colitis, sponsored by Sanofi.
NCT06975722 is a Phase 2 study of Ulcerative Colitis that is actively recruiting participants, run by Sanofi. The registered enrollment target is 99 participants, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06975722, a Phase 2 study of Ulcerative Colitis, is actively recruiting participants, sponsored by Sanofi.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 99 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase 2b, randomized, double-blind, 3-arm study for the treatment of Ulcerative Colitis. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Ulcerative Colitis. The total study duration is up to 168 weeks, with a treatment period of up to 158 weeks including an open-label (OL) long-term extension (LTE) period of up to 104 weeks for eligible participants.
Primary Outcome
Clinical remission is based on modified Mayo subscores. The mMS ranges from 0 to 9 with higher scores indicating greater disease severity.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG SAR442970
Study Locations (20)
Florida
- Investigational Site Number: 8400024 - Jacksonville
- Investigational Site Number: 8400030 - Kissimmee
- Investigational Site Number: 8400003 - Lighthouse PT
- Investigational Site Number: 8400001 - Miami
- Investigational Site Number: 8400011 - Miami
- Investigational Site Number: 8400010 - Palmetto Bay
- Investigational Site Number: 8400019 - Tampa
California
- Investigational Site Number: 8400009 - Escondido
- Investigational Site Number: 8400006 - Lancaster
- Investigational Site Number: 8400025 - Thousand Oaks
New York
- Investigational Site Number: 8400021 - New York
- Investigational Site Number: 8400029 - Queens Village
Georgia
- Investigational Site Number: 8400018 - Marietta
Iowa
- Investigational Site Number: 8400005 - Iowa City
Massachusetts
- Investigational Site Number: 8400017 - Boston
Michigan
- Investigational Site Number: 8400012 - Wyoming
Missouri
- Investigational Site Number: 8400014 - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2025-07-07 |
| Est. Completion | 2029-10-17 |
| Phase | Phase 2 |
What NCT06975722 shows while recruiting
NCT06975722 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 99 participants, a relatively small participant target, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Ulcerative Colitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06975722 names 20 study sites across 11 states, led by Florida, California, New York.
Frequently Asked Questions
What is clinical trial NCT06975722 about?
NCT06975722 is a clinical study titled "A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis". This is a phase 2b, randomized, double-blind, 3-arm study for the treatment of Ulcerative Colitis. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Ulcerative Colitis. The total study duration ...
What is the current status of trial NCT06975722?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2025-07-07. Estimated completion is 2029-10-17.
What conditions does trial NCT06975722 study?
This clinical trial studies the following conditions: Ulcerative Colitis.
What interventions are being tested in trial NCT06975722?
The interventions under investigation include: Placebo (DRUG), SAR442970 (DRUG).
Who is sponsoring clinical trial NCT06975722?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06975722 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Iowa, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06975722's enrollment target sits among peer trials
99 68th of 122 higher than 55 of 122 other Ulcerative Colitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ulcerative Colitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
RECRUITING · Phase 2
-
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
-
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
-
Treatment of UC With Novel Therapeutics
RECRUITING · Phase 2
-
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
RECRUITING · Phase 2
-
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03965234 · 99 participants · Phase 1
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
- NCT04022616 · 99 participants
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
- NCT04042844 · 99 participants · Phase 2
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
- NCT04143724 · 99 participants · Phase 2
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI